产品名称	HCC827人非小细胞肺癌细胞
货号	ZQ0386
产品介绍	HCC827是从一名 39 岁白人女性腺癌患者的肺部分离出的上皮细胞，这株肺腺癌在EGFR酪氨酸激酶区域有一个获得性突变(E746-A750缺失)，经常用于与表皮生长因子受体(EGFR)相关的研究。HCC827细胞对酪氨酸激酶抑制剂(TKIs)的敏感性很高，特别是那些靶向EGFR突变的细胞。这一特点使它们成为研究肺癌对EGFR抑制剂反应性的分子机制以及测试靶向EGFR依赖途径的新治疗剂功效的有价值的模型。 该细胞系还被用于探索靶向治疗获得性耐药机制，这是肺癌治疗中的一个重大挑战。利用HCC827细胞的研究有助于更好地了解对EGFR抑制剂产生耐药性的遗传和表观遗传改变。这些发现对开发克服耐药性和改善肺癌患者治疗结果的策略具有重要意义。此外，HCC827细胞系可作为研究肺腺癌更广泛的细胞和分子景观的工具，包括细胞信号传导、肿瘤微环境和癌症转移的研究。
种属	人
性别/年龄	女，39岁
组织	肺腺癌
疾病	肺腺癌
细胞类型	肿瘤细胞
形态学	上皮细胞
生长方式	贴壁
倍增时间	大约44.5~71小时
培养基和添加剂	RPMI-1640（品牌：中乔新舟 货号：ZQ-200）+10%FBS（品牌：中乔新舟 货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0386
生物安全等级	BSL-1
STR位点信息	Amelogenin: X CSF1PO: 11 D13S317: 9 D16S539: 12 D5S818: 12 D7S820: 11,12 TH01: 6 TPOX: 8 vWA: 18
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CRL-2868 BCRJ; 0351 DSMZ; ACC-566
供应限制	仅供科研使用

货号	ZQ0386
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： MicroRNA‐198‐5p inhibits the migration and invasion of non‐small lung cancer cells by targeting fucosyltransferase 8
DOI： 10.1111/1440-1681.13154
发表时间： 2019-08-30
期刊： CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
影响因子： 2.336
货号： ZQ0386
产品名称： HCC827 cells

原文链接： https://onlinelibrary.wiley.com/doi/abs/10.1111/1440-1681.13154

PubMed=9559342; DOI=10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2
Virmani A.K., Fong K.M., Kodagoda D.R., McIntire D., Hung J., Tonk V., Minna J.D., Gazdar A.F.
Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.
Genes Chromosomes Cancer 21:308-319(1998)

PubMed=10987304
Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Cancer Res. 60:4894-4906(2000)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=16187286; DOI=10.1002/ijc.21491
Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., Gazdar A.F., Lam S., MacAulay C., Lam W.L.
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
Int. J. Cancer 118:1556-1564(2006)

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025
Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Cell 131:1190-1203(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22751098; DOI=10.1038/ng.2330
Zhang Z.-F., Lee J.C., Lin L.-P., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X.-Q., Levine A.D., Rho J.K., Choi Y.J., Choi C.-M., Kim S.-W., Jang S.J., Park Y.S., Kim W.S., Lee D.H., Lee J.-S., Miller V.A., Arcila M.E., Ladanyi M., Moonsamy P., Sawyers C.L., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R., Halmos B., Bivona T.G.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nat. Genet. 44:852-860(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=23733853; DOI=10.1101/gr.152322.112
Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Genome Res. 23:1434-1445(2013)